20:15 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

DISEASE CATEGORY: Musculoskeletal INDICATION: Bone repair Cell culture and non-human primate studies identified chimera composed of BMP2, BMP6 and activin A sequences that could help repair bone.The chimera consists of human BMP2 engineered with substitutions...
19:11 , Apr 12, 2019 |  BC Week In Review  |  Clinical News

Acceleron discontinues ACE-2494 due to antidrug antibodies

Acceleron discontinued development of ACE-2494 due to the frequency of antidrug antibodies observed among healthy volunteers in a Phase I trial. Acceleron Pharma Inc. (NASDAQ:XLRN) was developing ACE-2494 as a potential treatment of neuromuscular disorders....
13:06 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

ACVR2B as target for heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure Patient sample and mouse studies suggest inhibiting ACVR2B could help treat heart failure. In 50 adults with severe aortic stenosis and heart failure, high plasma levels of activin A,...
20:02 , Nov 2, 2018 |  BC Week In Review  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Oct. 29,...
14:43 , Oct 30, 2018 |  BC Extra  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Monday, hours...
22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
19:27 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Blueprint debuts selective ALK2 inhibitor for rare musculoskeletal disease

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sept. 30....
15:30 , Sep 30, 2018 |  BC Extra  |  Preclinical News

Blueprint Medicines unveils preclinical data for rare bone disease program

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sunday. Blueprint...
19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
15:47 , Aug 30, 2018 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...